학술논문

When the Neighboring Village is Not Treated: Role of Geographic Proximity to Communities Not Receiving Mass Antibiotics for Trachoma.
Document Type
article
Source
Clinical Infectious Diseases. 76(6)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Infectious Diseases
Clinical Trials and Supportive Activities
Clinical Research
Eye Disease and Disorders of Vision
Infection
Good Health and Well Being
Child
Humans
Infant
Anti-Bacterial Agents
Trachoma
Azithromycin
Chlamydia trachomatis
Mass Drug Administration
Prevalence
trachoma
ocular chlamydia
geographic information systems
mass drug administration
azithromycin
Biological Sciences
Medical and Health Sciences
Microbiology
Clinical sciences
Language
Abstract
BackgroundMass administration of azithromycin is an established strategy for decreasing the prevalence of trachoma in endemic areas. However, nearby untreated communities could serve as a reservoir that may increase the chances of chlamydia reinfection in treated communities.MethodsAs part of a cluster-randomized trial in Ethiopia, 60 communities were randomized to receive mass azithromycin distributions and 12 communities were randomized to no treatments until after the first year. Ocular chlamydia was assessed from a random sample of children per community at baseline and month 12. Distances between treated and untreated communities were assessed from global positioning system coordinates collected for the study.ResultsThe pretreatment prevalence of ocular chlamydia among 0 to 9 year olds was 43% (95% confidence interval [CI], 39%-47%), which decreased to 11% (95% CI, 9%-14%) at the 12-month visit. The posttreatment prevalence of chlamydia was significantly higher in communities that were closer to an untreated community after adjusting for baseline prevalence and the number of mass treatments during the year (odds ratio, 1.12 [95% CI, 1.03-1.22] for each 1 km closer to an untreated community).ConclusionsMass azithromycin distributions to wide, contiguous geographic areas may reduce the likelihood of continued ocular chlamydia infection in the setting of mass antibiotic treatments.